ProQR Therapeutics (PRQR) Cash & Equivalents (2013 - 2025)

ProQR Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $107.6 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 32.62% year-over-year to $107.6 million; the TTM figure through Dec 2025 stood at $107.6 million (down 32.62% YoY), while the FY2025 annual figure was $107.6 million, down 32.62% from the prior year.
• Cash & Equivalents came in at $107.6 million for Q4 2025 at ProQR Therapeutics, down from $159.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $214.5 million in Q4 2021 to a low of $91.3 million in Q2 2021.
• A 5-year average of $145.7 million and a median of $144.6 million in 2023 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 137.25% in 2021 and fell as far as 99.93% in 2021.
• ProQR Therapeutics' Cash & Equivalents stood at $214.5 million in 2021, then tumbled by 54.93% to $96.7 million in 2022, then soared by 32.33% to $128.0 million in 2023, then rose by 24.77% to $159.7 million in 2024, then sank by 32.62% to $107.6 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $107.6 million, $159.7 million, and $128.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison